share_log

SVB Leerink Maintains Outperform on Theravance Biopharma, Raises Price Target to $14

Benzinga Real-time News ·  Nov 17, 2022 06:04

SVB Leerink analyst David Risinger maintains Theravance Biopharma (NASDAQ:TBPH) with a Outperform and raises the price target from $12 to $14.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment